These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 15179403)

  • 1. Postmarketing surveillance for drug safety: surely we can do better.
    Griffin MR; Stein CM; Ray WA
    Clin Pharmacol Ther; 2004 Jun; 75(6):491-4. PubMed ID: 15179403
    [No Abstract]   [Full Text] [Related]  

  • 2. [The observational post-marketing study--an observation of use].
    Meister W
    Dtsch Med Wochenschr; 2003 Apr; 128(16):859-62. PubMed ID: 12701030
    [No Abstract]   [Full Text] [Related]  

  • 3. [Patient safety first. position paper of the German Rheumatism -- Ligazur introduction of biosimilars].
    Z Rheumatol; 2014 Sep; 73(7):676. PubMed ID: 25320752
    [No Abstract]   [Full Text] [Related]  

  • 4. [Critical study of methods of postmarketing drug surveillance].
    Gut JP; Auriche M; Spriet-Pourra C; Juillet Y
    Therapie; 1985; 40(5):313-9. PubMed ID: 3913048
    [No Abstract]   [Full Text] [Related]  

  • 5. Post-marketing strategies for medicines.
    Breckenridge A
    Clin Pharmacol Ther; 2008 Jan; 83(1):24-5; discussion 25. PubMed ID: 18043682
    [No Abstract]   [Full Text] [Related]  

  • 6. Industry reneges on postmarketing trial commitments.
    Bouchie A
    Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074
    [No Abstract]   [Full Text] [Related]  

  • 7. [The Netherlands and postmarketing surveillance].
    Wesseling H
    Ned Tijdschr Geneeskd; 1992 Jan; 136(1):7-8. PubMed ID: 1728764
    [No Abstract]   [Full Text] [Related]  

  • 8. [How to report side-effects of drugs?].
    Guillaume JC
    Ann Dermatol Venereol; 1986; 113(4):375-6. PubMed ID: 3767239
    [No Abstract]   [Full Text] [Related]  

  • 9. [Drug surveillance. Which methods? For which adverse effects? Application to teratogen monitoring].
    Goujard J
    Therapie; 1985; 40(5):287-92. PubMed ID: 4095683
    [No Abstract]   [Full Text] [Related]  

  • 10. Postmarketing modifications in the safety labeling of the new antiepileptics.
    Buck ML; Gurka MJ; Goodkin HP
    Neurology; 2007 May; 68(18):1536-7. PubMed ID: 17470758
    [No Abstract]   [Full Text] [Related]  

  • 11. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept.
    Feltelius N; Fored CM; Blomqvist P; Bertilsson L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L;
    Ann Rheum Dis; 2005 Feb; 64(2):246-52. PubMed ID: 15208177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The FDA and safety--beyond the heparin crisis.
    Laurencin CT; Nair L
    Nat Biotechnol; 2008 Jun; 26(6):621-3. PubMed ID: 18536680
    [No Abstract]   [Full Text] [Related]  

  • 13. European biologicals registers: methodology, selected results and perspectives.
    Zink A; Askling J; Dixon WG; Klareskog L; Silman AJ; Symmons DP
    Ann Rheum Dis; 2009 Aug; 68(8):1240-6. PubMed ID: 18647854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bayesian approach to the imputability of undesirable phenomena to drugs].
    Auriche M
    Therapie; 1985; 40(5):301-6. PubMed ID: 4095686
    [No Abstract]   [Full Text] [Related]  

  • 15. Canaries, coal mines and the drug supply.
    Leiden JM
    Nat Biotechnol; 2008 Jun; 26(6):624-6. PubMed ID: 18536681
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pharmacologic surveillance and safety of drugs: reflexions for legislative and, especially, cultural action].
    Laporte JR
    Rev Med Univ Navarra; 1988; 32(1):31-3. PubMed ID: 3154929
    [No Abstract]   [Full Text] [Related]  

  • 17. A call for international harmonization in therapeutic risk management.
    Hirst C; Cook S; Dai W; Perez-Gutthann S; Andrews E
    Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):839-49; discussion 850-1. PubMed ID: 16981215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sensitivity and specificity of imputability criteria. Study and comparison of these efficacity indices for 7 methods].
    Péré JC; Godin MH; Bégaud B; Haramburu F; Albin H
    Therapie; 1985; 40(5):307-12. PubMed ID: 4095687
    [No Abstract]   [Full Text] [Related]  

  • 19. [A network of regional correspondents for studying undesirable effects].
    Haramburu F; Péré JC; Begaud B; Albin H
    Therapie; 1985; 40(5):321-4. PubMed ID: 4095688
    [No Abstract]   [Full Text] [Related]  

  • 20. An overview of spontaneous reporting of adverse drug reactions (ARDs) in Zimbabwe.
    Ball D
    Cent Afr J Med; 2000 Jan; 46(1):23-4. PubMed ID: 14674204
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.